Soluble CD23 doubling time a possible prognostic factor in CLL

Keating, Michael
September 2008
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p22
The article discusses research being done on soluble CD23. It references a study which appeared in the 2008 issue of "Leukemia." The study evaluated whether soluble CD23 doubling time was a prognostic factor for patients with diagnosed and untreated chronic lymphocytic leukemia (CLL). The researchers also compared soluble CD23 doubling time with lymphocyte doubling time, immunoglobulin variable heavy chain mutational status, and lipoprotein lipase (LPL) expression.


Related Articles

  • A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia. Sportoletti, P; Baldoni, S; Del Papa, B; Aureli, P; Dorillo, E; Ruggeri, L; Plebani, S; Amico, V; Di Tommaso, A; Rosati, E; Marconi, P; Di Ianni, M; Falzetti, F // Leukemia (08876924);Feb2014, Vol. 28 Issue 2, p436 

    A letter to the editor is presented which discusses the activating mutations of NOTCH1 in chronic lymphocytic leukemia (CLL) patients.

  • Correction: Lipoprotein Lipase SNPs rs13702 and rs301 Correlate with Clinical Outcome in Chronic Lymphocytic Leukemia Patients. null, null // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    No abstract available.

  • Lipoprotein Lipase SNPs rs13702 and rs301 Correlate with Clinical Outcome in Chronic Lymphocytic Leukemia Patients. Rombout, Ans; Stamatopoulos, Basile; Lagneaux, Laurence; Lust, Sofie; Offner, Fritz; Naessens, Evelien; Vanderstraeten, Hanne; Verhasselt, Bruno; Philippé, Jan // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and is characterized by a heterogeneous clinical course. This variability in clinical course has spiked the search for prognostic markers able to predict patient evolution at the moment of diagnosis. Markers...

  • Evolution: Deep down. McCarthy, Nicola // Nature Reviews Cancer;Oct2008, Vol. 8 Issue 10, p738 

    The article presents the study of Peter Campbell, Mike Stratton and colleagues to identify related clones in the evolution of tumors in patients with chronic lymphocytic leukaemia (CLL). The authors utilize the ultra-deep pyrosequencing to examine the mutations in CLL clonal B-cell tumor which...

  • Chimeric Antigen Receptor�Modified T Cells in Chronic Lymphoid Leukemia. Porter, David L.; Levine, Bruce L.; Kalos, Michael; Bagg, Adam; June, Carl H. // New England Journal of Medicine;8/25/2011, Vol. 365 Issue 8, p725 

    We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. A low dose...

  • Reverse Pseudohyperkalemia: An Important Clinical Entity in Chronic Lymphocytic Leukemia. Mansoor, Sahar; Holtzman, Noa G.; Emadi, Ashkan // Case Reports in Hematology;9/27/2015, Vol. 2015, p1 

    Hyperkalemia is a potentially lethal electrolyte derangement commonly seen in patients with hematologic neoplasms with or without renal failure. Pseudohyperkalemia and reverse pseudohyperkalemia also can be seen in this patient population and early recognition and diagnosis of these conditions...

  • Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia. Hartman, Mariusz L.; Kilianska, Zofia M. // Contemporary Oncology / Wspolczesna Onkologia;2012, Vol. 16 Issue 6, p474 

    The clinical course of patientswith chronic lymphocytic leukemia (CLL) is highly heterogeneous. Gene expression analyses have revealed that leukemic cells with unmutated immunoglobulin heavy chain genes (IgVH) differ from CLL cells with mutated IgVH in the expression level of some genes, i.e....

  • Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Fox, Christopher // Current Medical Literature: Leukemia & Lymphoma;2014, Vol. 22 Issue 2, p46 

    The article discusses a study published in the journal "Blood" which evaluated mutations of tumor protein p53 (TP53) gene in chronic lymphocytic leukemia (CLL) patients. Topics include clinical insight on TP53 mutation as an accurate indicator of CLL prognosis, the application of next-generation...

  • NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Bo, Michele; Principe, Maria Ilaria; Pozzo, Federico; Ragusa, Dario; Bulian, Pietro; Rossi, Davide; Capelli, Giovanni; Rossi, Francesca; Niscola, Pasquale; Buccisano, Francesco; Bomben, Riccardo; Zucchetto, Antonella; Maurillo, Luca; Fabritiis, Paolo; Amadori, Sergio; Gaidano, Gianluca; Gattei, Valter; Poeta, Giovanni // Annals of Hematology;Oct2014, Vol. 93 Issue 10, p1765 

    Induction therapy with fludarabine followed by rituximab and consolidation plus maintenance with rituximab improved response duration (RD) and overall survival (OS) in our patients with chronic lymphocytic leukemia (CLL). The aim of our study was to investigate the clinical impact of NOTCH1...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics